Topics

AbbVie's Skyrizi outpaces Novartis' Cosentyx in plaque psoriasis skin clearance

06:06 EST 16 Jan 2020 | Pharmafile

AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque psoriasis, hitting both its primary and all ranked secondary endpoints.

The data revealed “significantly higher” skin clearance rates for Skyrizi compared to Cosentyx, with 87% experiencing an improvement of at least 90% from baseline at 52 weeks of treatment, according to the Psoriasis Area and Severity Index (PASI), compared to just 57% with the latter.

read more

Original Article: AbbVie's Skyrizi outpaces Novartis' Cosentyx in plaque psoriasis skin clearance

NEXT ARTICLE

More From BioPortfolio on "AbbVie's Skyrizi outpaces Novartis' Cosentyx in plaque psoriasis skin clearance"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...